| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers
|
Akhtar, Aamna
|
|
|
23 |
4 |
p. 356-363
|
article
|
| 2 |
A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)
|
Shiraishi, Yoshimasa
|
|
|
23 |
4 |
p. e285-e288
|
article
|
| 3 |
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib
|
Camidge, D. Ross
|
|
|
23 |
4 |
p. 300-310
|
article
|
| 4 |
Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report
|
Hochmair, Maximilian Johannes
|
|
|
23 |
4 |
p. e289-e292
|
article
|
| 5 |
Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations
|
Harris, Jeremy P
|
|
|
23 |
4 |
p. 333-344
|
article
|
| 6 |
Corrigendum to “Docetaxel downregulates PD-1 expression via STAT3 in Tlymphocytes” [Clinical Lung Cancer 19 (2018) e675-e683]
|
Zhang, Chaoyang
|
|
|
23 |
4 |
p. 374-376
|
article
|
| 7 |
Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy
|
Andraos, Therese Y.
|
|
|
23 |
4 |
p. 291-299
|
article
|
| 8 |
Editorial Board
|
|
|
|
23 |
4 |
p. A1
|
article
|
| 9 |
Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer
|
Zhang, Lihong
|
|
|
23 |
4 |
p. 311-319
|
article
|
| 10 |
Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma
|
Kee, Wanyi
|
|
|
23 |
4 |
p. e293-e295
|
article
|
| 11 |
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non–squamous Non–small Cell Lung Cancer After Progression on Platinum and Pemetrexed
|
Ciunci, Christine A
|
|
|
23 |
4 |
p. e310-e316
|
article
|
| 12 |
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy
|
Marmarelis, Melina E.
|
|
|
23 |
4 |
p. e301-e309
|
article
|
| 13 |
Primary Pulmonary NUT Carcinoma: Case Illustration and Updated Review of Literature
|
Costa, Bruno Almeida
|
|
|
23 |
4 |
p. e296-e300
|
article
|
| 14 |
Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa – KINDLE Study
|
Jazieh, A.R.
|
|
|
23 |
4 |
p. 364-373
|
article
|
| 15 |
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
|
Veillon, Remi
|
|
|
23 |
4 |
p. 320-332
|
article
|
| 16 |
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy
|
Guo, Yizhen
|
|
|
23 |
4 |
p. 345-355
|
article
|
| 17 |
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation
|
Federico, Alessandro Di
|
|
|
23 |
4 |
p. e283-e284
|
article
|
| 18 |
Table of Contents
|
|
|
|
23 |
4 |
p. A3-A5
|
article
|
Journal description